|
Indian Pediatr 2011;48: 363-364 |
![](../Home_files/coverin.gif) |
H1N1 2009 Pandemic - Lessons learnt |
Nitin K Shah
Consultant Pediatrician, PD Hinduja National Hospital,
Mumbai, India.
Email: [email protected]
|
On 11 June, 2009, WHO declared
phase 6 of the 1st influenza pandemic of the
current century caused by pandemic
H1N1 2009 strain. On 10 August, 2010, WHO announced that the world was in
post-pandemic phase, though fresh cases continued to be reported from
India till the end of September 2010 [1,2].
Pandemic H1N1 2009 infection, though milder than
previous influenza pandemics and with less mortality, affected healthy
young people more often than the elderly people; 25-50% of cases who were
hospitalized or died had no co-morbidities [3]. In contrast, in this issue
of Indian Pediatrics, Das et al, reported that all children
with co-morbidities required hospitalization [4]. In India, 33% of cases
were reported in 5-19 years of age group and 40% in 20-39 years of age
group [2]. Mortality due to pandemic H1N1 2009 has been estimated to be
<0.5% (0.0004-1.47%), but it is difficult to estimate as many cases are
mild or sub-clinical giving an incorrect denominator [3]. This is also
evident from a seroepidemiology study done from Pune during the 2009
pandemic which showed that the peak seroprevalence was 20% in hospital
staff, 35.6% in general medical practitioners, 26% in school staff, 7.7%
in adult general population, 13.2% in children general population, 28.3%
in 15-19 years general population and only 3.5% in those older than 60
years [5]. Media played its role in blowing up the pandemic cases and
deaths which created a fear psychosis amongst patients and the treating
practitioners alike and highlighted the country’s poor preparedness for
the pandemic. Transferring a sick patient to a facility with isolation was
a nightmare for the practicing pediatricians due to lack of isolation
wards. Experts of the IAP (Indian Academy of Pediatrics), Mumbai branch,
prepared local guide-lines to manage pandemic influenza following which
the Central IAP and the IAP Infectious Disease Chapter adopted IAP
guidelines for the same. The Ministry of Health and Family Welfare,
Government of India, also put up the National guidelines on the website
which clearly defined the categories of suspected pandemic H1N1 2009 cases
and guide-lines for testing and treatment with oseltamivir [6]. The
confusion persisted though with contrary local guidelines for Maharashtra
[7]. Dissipation of national guidelines to medical fraternity was a
challenge and was partially met by infomercials in media. Efficacy of
measures like wearing ordinary face masks and closing of schools was
questionable as in Pune, where despite these measures, the virus infected
a significant percentage of population. Developing an effective
distribution system for oseltamivir was a herculean task and the price in
private market remained exorbitant. One positive aspect of the whole
pandemic was an increased awareness about personal hygiene, especially
hand sanitization, which is practiced by many even today routinely.
World over, monovalent pandemic H1N1 2009 vaccines were
available in late 2009 but only to the developed countries. Enough stocks
were available only by late August 2010 when they reached India and by
then the pandemic was declared as over! IAP COI was prompt in adopting
guidelines on the use of pandemic and seasonal 2010 influenza vaccine; and
now that the vaccines are available, we are all reluctant to use it
thinking that the pandemic is over! Unless we have a national policy on
the use of influenza vaccine, the situation will not improve and we will
face the same music even during the next pandemic whenever it occurs!
There are millions of ‘at risk’ persons including children in India who
always needed influenza vaccine every year, and IAP has for long
recommended influenza vaccine for these ‘at risk’ individuals, and yet a
miniscule of these persons are actually offered the vaccine. The bright
side of the story is that indigenous manufacturers from India did come
out with a monovalent H1N1 2009 vaccine and hope to follow it up with
trivalent influenza vaccine this year. This will go a long way in
obviating the dependence on foreign manufacturers and also help bring down
the price of influenza vaccines in India in future.
A post-pandemic phase does not mean the end of pandemic
H1N1 2009 infection, it only means that the peak of transmission of
pandemic H1N1 2009 is over and it is expected that pandemic H1N1 2009 will
now co-circulate with other seasonal influenza A and B stains. In the
post-pandemic period, cases and outbreaks due to the pandemic H1N1 2009
are expected to continue to occur. In addition, it is most likely that for
some period of time, the younger age groups, including pregnant women,
will continue to be affected disproportionately by severe disease from
pandemic H1N1 2009, including viral pneumonia. Pandemic H1N1 2009 may be
down but is certainly not out [8,9]. Hence, a continued surveillance for
influenza is required by all the countries to monitor the situation.
To conclude; the lessons learnt from influenza pandemic
from the the Indian perspective are that we need to be better prepared for
the pandemic in future, we need to have a long term policy on influenza
surveillance and use of influenza vaccine, we need to be more methodical
in our approach to a future outbreak of any infection or medical emergency
and we need to have evidence based scientific guidelines to tackle such a
medical emergency rather than giving a knee-jerk response in future!
Competing interests: The author received
general consultancy fees and speaker’s honoraria from Sanofi Pasteur India
and GSK India both of which manufacture and market influenza vaccines.
Funding: None.
References
1. WHO. Pandemic (H1N1) 2009 - update 112. Available at
http://www.who.int/csr/don/2010_08_06/en/index.html. Accessed on December
24, 2010.
2. MOHFW GOI. Situation Update on H1N1. Available at
http://mohfw-h1n1.nic.in/documents/PDF/EpidemiologicalTrendsInIndia.pdf.
Accessed on December 24, 2010.
3. Writing Committee of the WHO Consultation on
Clinical Aspects of Pandemic (H1N1) 2009 Influenza. Clinical Aspects of
Pandemic 2009 Influenza A (H1N1) Virus Infection. N Engl J Med.
2010;362:1708-19.
4. Das RR, Sami A, Lodha R, Jain R, Broor S, Kaushik S,
et al. Clinical profile and outcome of swine flu in Indian
children. Indian Pediatr. 2010;48:373-8.
5. Tandale BV, Pawar SD, Gurav YK, Chadha MS, Kuratkar
MS, Shelke VN et al. Seroepidemiology of pandemic influenza A
(H1N1) 2009 virus infection in Pune India. Poster presentation no. P-277
Abstract book of the conference Epidemiology, Disease burden and Health
Economics, Options for the control of Influenza infection VII held at Honk
Kong, 2010. p. 210.
6. MOHFW GOI. Guidelines on categorization of influenza
A H1N1 cases during screening for home isolation, testing, treatment and
hospitalization. Available at http://mohfw-h1n1.nic.in. Accessed on 4
October, 2009.
7. Shah N. H1N1 guidelines – reply. Indian Pediatr.
2010;47:102-3.
8. Prevention and Control of Influenza with Vaccines
Recommendations of the Advisory Committee on Immunization Practices (ACIP),
2010. MMWR. 2010;59:1-64.
9. WHO. Influenza Update – 17 December 2010. Available at http://www.who.int/csr/disease/influenza/2010_12_17_GIP_surveillance/en/index.html
Accessed on 24 December, 2010.
|
|
![](../Home_files/iap.jpg) |
|